Company profile: Lycia Therapeutics
1.1 - Company Overview
Company description
- Provider of lysosome-targeting chimeras (LYTAC) technology for developing therapeutics that target and degrade extracellular and membrane-bound proteins for a range of diseases. Offers the LYTAC platform and a discovery pipeline of degraders for autoimmune and inflammatory conditions and cancer, and maintains a strategic collaboration with Lilly focused on immunology and pain.
Products and services
- LYTAC Platform: Custom-engineered platform that engineers therapeutics using lysosome-targeting chimeras to degrade extracellular and membrane-bound proteins implicated in diverse diseases
- Discovery Pipeline: Discovery-stage portfolio of novel LYTAC degraders to target extracellular and membrane proteins underlying autoimmune, inflammatory conditions, and cancer
- Strategic Collaboration with Lilly: Platform-enabled partnership that architects and advances novel LYTAC-based therapeutics, concentrating on immunology and pain
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Lycia Therapeutics
SciBase
HQ: Sweden
Website
- Description: Provider of medical devices leveraging Electrical Impedance Spectroscopy (EIS) to detect malignant melanoma and assess skin barrier function. Products include Nevisense, a point-of-care platform using EIS and AI for non-invasive melanoma detection and objective clinical decision-making, and Nevisense Go, a portable EIS device for detailed skin barrier assessment in research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SciBase company profile →
Neogene Therapeutics
HQ: The Netherlands
Website
- Description: Provider of T cell therapies targeting cancer neo-antigens, developing technologies to engineer designer T cells with optimized neo-antigen specificities to seek and destroy cancer cells. Offers engineered TCR therapies for solid tumors, including a TP53 R175H-targeting TCR therapy currently in Phase I trials in the US.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neogene Therapeutics company profile →
ME Therapeutics
HQ: Canada
Website
- Description: Provider of biotechnology drug discovery and development focused on myeloid cell-targeted immuno-oncology therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ME Therapeutics company profile →
Oncimmune
HQ: United Kingdom
Website
- Description: Provider of proprietary autoantibody assay technologies for early cancer detection, offering ImmunoINSIGHTS analytical platform to discover and profile autoantibody biomarkers for disease characterization, patient stratification, and response prediction; biomarker discovery services; customizable targeted panels and arrays for immuno-oncology and autoimmune diseases; and bioinformatics and data science with multiomics integration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncimmune company profile →
C4X Discovery
HQ: United Kingdom
Website
- Description: Provider of NMR-based 3D molecular structure determination to optimize drug design and development, partnering with pharma to generate better, safer products. Offers Conformetrix 4D structural design technology, 4Sight visualizer, PatientSeek for genetic patient stratification, and programs including oral α4β7 integrin inhibitors, IL-17A inhibitors (licensed to Sanofi), and NRF2 activators (licensed to AstraZeneca).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full C4X Discovery company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Lycia Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Lycia Therapeutics
2.2 - Growth funds investing in similar companies to Lycia Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Lycia Therapeutics
4.2 - Public trading comparable groups for Lycia Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →